Project Grant K08CA308866
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $136K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), awarded a $112,230 project grant to The University of Texas MD Anderson Cancer Center for research investigating antigen spread following Type 1 Conventional Dendritic Cell (CDC1) vaccination. The three-year project, which commenced on September 10, 2025 and concludes on September 9, 2028, will deliver pre-clinical research services examining how CDC1 vaccination...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $421,685 project grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded August 1, 2025, with a completion date of July 31, 2027. This award supports research investigating the LIFR-LCN2 pathway as a novel mechanism of immune suppression in hepatocellular carcinoma (HCC). The research aims to elucidate how loss of LIFR upregulates LCN2, leading to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $616,715 to The University of Texas MD Anderson Cancer Center, with an award date of August 11, 2025 and completion date of July 31, 2030. This award supports research under the Cancer Treatment Research program (CFDA 93.395), which develops and evaluates improved methods of cancer treatment through fundamental and applied laboratory and clinical research. The funded research centers on the...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $421,685 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The University of Texas MD Anderson Cancer Center, effective August 1, 2025, through July 31, 2027. This award supports pan-cancer analysis of convergent immunoglobulins from tumor-infiltrating B cells (TIL-B), with the primary deliverable being the identification and characterization of shared B cell receptors (BCR) and antibodies across...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $370,173 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded September 9, 2025, with a completion date of August 31, 2030. This project delivers research and development of advanced genetic interaction measurement and characterization methodologies for cancer cells, with a primary focus on synthetic lethality as a...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $932,350 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 15, 2025, through August 14, 2028. The grant supports the development and evaluation of an in situ tumor vaccine designed to stimulate antitumor immunity against breast cancer. This three-year research initiative will be conducted at MD...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Texas at Austin a $2.59 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. The award supports research to develop a novel cancer immunotherapy approach targeting immune-excluded or "cold" tumors that typically demonstrate poor response to immune checkpoint therapy. The project focuses on demonstrating that degradation of...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $402,011 Project Grant to The University of Texas Southwestern Medical Center (UT Southwestern) under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This five-year award funds fundamental research investigating the KEAP1-NRF2 redox sensing pathway's role in regulating CD8 T cell adaptation and stemness in the context of cancer and chronic infection. The research...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), awarded a $112,806 project grant to The University of Texas MD Anderson Cancer Center effective December 1, 2025, with completion by April 30, 2028. This award supports research investigating the role of CARM1-mediated methylation of QKI (quaking) in glioblastoma, a project designed to advance understanding of glioblastoma stem cell maintenance mechanisms. The...